Less than a week after Roche pledged a hefty investment in the South Korean biopharma industry, Eli Lilly is following suit with a $500 million, five-year pact of its own. | Less than a week after ...

Molecular glue-focused biotech f5 Therapeutics has failed to stick around for the long haul, shuttering after six years, according to an ...

Voyager Therapeutics has hit pause on a preclinical Alzheimer’s disease program just eight months after unveiling the asset. The neurology biotech announced back in July 2025 that it was adding a new ...

The Delphi initiative—tied to the Greek oracle’s maxim “know thyself”—aims to support modular, chip-like sensors that could work in a variety of devices.

Wisconsin Sen. Ron Johnson is asking to see several of the complete response letters that have been delivered of late and also told Bloomberg that he may call on top FDA leaders to testify before the ...

Ascletis Pharma has posted phase 2 data on its ultra-long-acting GLP-1 receptor analog, generating early evidence that the formulation may support quarterly dosing as a maintenance therapy. Eli ...

San Francisco venture capital firm Breakout Ventures announced the close of a $114 million fund to support founder-led companies working at the nexus of science and artificial intelligence. | San ...

Uğur Şahin, M.D., who is currently the CEO of BioNTech, and his wife Özlem Türeci, M.D., who is chief medical officer, founded mRNA-focused BioNTech in 2008. The company rose to prominence and ...

Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more ...

Vertex reported a phase 3 win for its kidney disease prospect povetacicept, meeting analyst expectations and firing the starting gun on a race to the FDA that could result in an accelerated approval ...

LifeVac has picked up a groundbreaking clearance from the FDA for its suction-powered device designed to dislodge an object ...

AbbVie has unveiled the first data from its $350 million obesity bet, with the amylin analog demonstrating weight loss of close to 10% after 12 weeks in one dose cohort.